InflaRx N.V. (NASDAQ: IFRX)

Introduction

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize inhibitors of the complement activation factor C5a and its receptor C5aR. These inhibitors are intended to target autoimmune and inflammatory diseases by modulating immune responses.

Corporate Structure

• Founded: 2007
• Headquarters: Jena and Munich, Germany; Ann Arbor, Michigan, USA
• Employees: 51–200
• Exchange: Nasdaq (Ticker: IFRX)

Recent Developments and News

• May 28, 2025
  • An Independent Data Monitoring Committee recommended stopping the Phase 3 trial of vilobelimab in pyoderma gangrenosum due to a determination of futility. InflaRx will discontinue the development for this indication and reallocate resources to INF904.
• April 2023
  • The U.S. FDA issued an Emergency Use Authorization (EUA) for GOHIBIC® (vilobelimab) for COVID-19 treatment in hospitalized adults requiring invasive mechanical ventilation or ECMO, administered within 48 hours. GOHIBIC is not authorized for non-emergency use in the U.S. and has received European Commission approval for SARS-CoV-2-induced ARDS.
• May 7, 2025
  • The first quarter 2025 financial results were published, highlighting a cash runway anticipated to last into 2027. Management indicated that an interim analysis of the vilobelimab Phase 3 trial is expected by the end of May 2025, along with topline data for the INF904 Phase 2a study anticipated in summer 2025.
• March 27, 2025
  • InflaRx achieved a recruitment milestone of 30 patients in the Phase 3 trial for pyoderma gangrenosum, aiding the planned interim analysis.
• Investor Conferences
  • Jefferies Global Healthcare Conference (June 3–5, 2025)
  • Oppenheimer Innovators in I&I Summit (June 25, 2025)
  • Leerink Partners Therapeutics Forum (July 8–9, 2025)

Financial and Strategic Analysis

Metric	Value
Share price (May 28, 2025)	USD 0.7950
Change vs. prior close	–56.32%
Volume	418,889
Market cap	USD 123.3 M
Enterprise value	USD 49.1 M
Price/Sales (ttm)	740.41
Price/Book (mrq)	1.54
Revenue (ttm)	USD 0.13 M
Net loss (ttm)	USD 44.72 M
Diluted EPS (ttm)	–0.84
Total cash & equivalents (mrq)	USD 65.86 M
Total debt/Equity (mrq)	1.0%
Levered free cash flow (ttm)	USD 34.37 M

• The share price has decreased from a 52-week high of USD 2.8150 to USD 0.7950.
• The average daily trading volume is approximately 300,500 shares.
• Current cash reserves and marketable securities are projected to support operations through 2027.
• The discontinuation of one Phase 3 program is expected to reduce near-term research and development expenditures, allowing a shift of focus to INF904, with Phase 2a results expected in summer 2025.

Market Position and Industry Context

InflaRx operates within the immunology and inflammation sector, with a focus on complement pathway modulation. The company has a beta of 1.59, suggesting higher volatility relative to the market. Current valuation metrics reflect the inherent risks associated with early-stage clinical development (Price/Sales > 700x, negative EPS). Upcoming data from INF904 and the continued regulatory support for vilobelimab under EUA and European Commission approval could provide potential growth catalysts.

tl;dr

• May 28, 2025: Phase 3 vilobelimab trial in pyoderma gangrenosum halted; program discontinued.
• Phase 2a topline data for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa expected summer 2025.
• Q1 2025 results (May 7, 2025) indicate financial stability with a cash runway into 2027.
• Current share price is USD 0.7950 (–56.32%); market cap USD 123.3 M.
• Upcoming investor events: Jefferies (June 3–5), Oppenheimer (June 25), Leerink (July 8–9), 2025.